Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Roche goes ona buying spree

April 9, 2007 | A version of this story appeared in Volume 85, Issue 15

Roche is acquiring two companies in diagnostics and one in antibodies. The Swiss drugmaker will acquire BioVeris, a maker of health care diagnostics, for about $600 million. Roche says the purchase will add electrochemiluminescence technology and allow it to "fully exploit the entire immunochemistry market." Roche is buying CuraGen's 454 Life Sciences unit, a developer of sequencing technology, for about $160 million. Roche Diagnostics has been distributing 454 Life Sciences' Genome Sequencer systems and associated reagents. And Roche has purchased privately held Therapeutic Human Polyclonals for $56.5 million. Roche says THP has developed a unique transgenic mammalian platform to create human antibodies.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.